{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:03:19Z","timestamp":1719187399562},"reference-count":114,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2013,9,30]]},"DOI":"10.2217\/fon.13.134","type":"journal-article","created":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T11:24:07Z","timestamp":1377689047000},"page":"1283-1298","source":"Crossref","is-referenced-by-count":3,"title":["Rituximab for the Treatment of Follicular Lymphoma"],"prefix":"10.1080","volume":"9","author":[{"given":"Chan Y","family":"Cheah","sequence":"first","affiliation":[{"name":"Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthil","family":"Lingaratnam","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F","family":"Seymour","sequence":"additional","affiliation":[{"name":"University of Melbourne, Parkville, Victoria, Australia"},{"name":"Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,8,28]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1202-y"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25149"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.3.592.592"},{"issue":"2","key":"e_1_3_2_3_7_1","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.","volume":"25","author":"Young RC","year":"1988","unstructured":"Young RC , LongoDL, GlatsteinE, IhdeDC, JaffeES, DevitaVTJr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.Semin. Hematol.25(2 Suppl. 2), 11\u201316 (1988).","journal-title":"Semin. Hematol."},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl162"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"issue":"11","key":"e_1_3_2_3_12_1","first-page":"790","article-title":"Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma.","volume":"110","author":"Al-Tourah AJ","year":"2007","unstructured":"Al-Tourah AJ , SavageKJ, GillKKet al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annual Meeting Abstracts 110(11), 790 (2007).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0258-4"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.09.008"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(03)00112-3"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04803.x"},{"issue":"6","key":"e_1_3_2_3_19_1","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies.","volume":"2","author":"Boross P","year":"2012","unstructured":"Boross P , LeusenJH. Mechanisms of action of CD20 antibodies.Am. J. Cancer Res.2(6), 676\u2013690 (2012).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.12.007"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056829"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1255"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001024"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1403"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2600"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263533"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1429"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.037390"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq027"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-378323"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2012.02827.x"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.781169"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298356"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408773"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01809.x"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0850"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01601.x"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7211"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02241.x"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269753"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265313133"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.09.004"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000184162.60197.c1"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380949"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg201"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.059246"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.171"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0469"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1089\/108497802320970226"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175125"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431825"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.10.3052"},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_3_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.052"},{"issue":"21","key":"e_1_3_2_3_75_1","first-page":"LBA-6","article-title":"Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma.","volume":"118","author":"Kahl BS","year":"2011","unstructured":"Kahl BS , HongF, WilliamsMEet al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. ASH Annual Meeting Abstracts 118(21), LBA-6 (2011).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"issue":"21","key":"e_1_3_2_3_78_1","first-page":"6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis.","volume":"116","author":"Ardeshna KM","year":"2010","unstructured":"Ardeshna KM , QianW, SmithPet al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. ASH Annual Meeting Abstracts 116(21), 6 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_3_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr418"},{"key":"e_1_3_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_3_2_3_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1862"},{"key":"e_1_3_2_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007"},{"key":"e_1_3_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902750114"},{"key":"e_1_3_2_3_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_3_2_3_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1639-9"},{"key":"e_1_3_2_3_88_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03166.x"},{"key":"e_1_3_2_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"e_1_3_2_3_90_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1004095"},{"key":"e_1_3_2_3_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9813-x"},{"key":"e_1_3_2_3_92_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.742524"},{"key":"e_1_3_2_3_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20864"},{"key":"e_1_3_2_3_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)31105-8"},{"key":"e_1_3_2_3_95_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612453849"},{"key":"e_1_3_2_3_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"e_1_3_2_3_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-163493"},{"key":"e_1_3_2_3_98_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.509456"},{"key":"e_1_3_2_3_99_1","first-page":"CD003805","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma.","volume":"4","author":"Schulz H","year":"2007","unstructured":"Schulz H , BohliusJ, SkoetzNet al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma. Cochrane Database Syst. Rev. 4, CD003805 (2007).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21818"},{"key":"e_1_3_2_3_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0274"},{"key":"e_1_3_2_3_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"e_1_3_2_3_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_3_2_3_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.3023"},{"issue":"21","key":"e_1_3_2_3_105_1","first-page":"901","article-title":"Lenalidomide and rituximab for untreated indolent lymphoma: final results of a Phase II study.","volume":"120","author":"Fowler NH","year":"2012","unstructured":"Fowler NH , NeelapuSS, HagemeisterFBet al. Lenalidomide and rituximab for untreated indolent lymphoma: final results of a Phase II study. ASH Annual Meeting Abstracts 120(21), 901 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_3_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"e_1_3_2_3_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"issue":"21","key":"e_1_3_2_3_108_1","first-page":"156","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma.","volume":"120","author":"Fowler NH","year":"2012","unstructured":"Fowler NH , AdvaniRH, SharmanJet al. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. ASH Annual Meeting Abstracts 120(21), 156 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"e_1_3_2_3_109_1","first-page":"3943","article-title":"Navitoclax (ABT-263) Plus rituximab: interim results of a Phase 1 study in patients with CD20-positive lymphoid malignancies.","volume":"116","author":"Kahl B","year":"2010","unstructured":"Kahl B , RobertsAW, SeymourJFet al. Navitoclax (ABT-263) Plus rituximab: interim results of a Phase 1 study in patients with CD20-positive lymphoid malignancies. ASH Annual Meeting Abstracts 116(21), 3943 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"e_1_3_2_3_110_1","first-page":"1643","article-title":"A Phase I trial of the Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL).","volume":"120","author":"Blum KA","year":"2012","unstructured":"Blum KA , ChristianB, FlynnJMet al. A Phase I trial of the Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL). ASH Annual Meeting Abstracts 120(21), 1643 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"e_1_3_2_3_111_1","first-page":"1629","article-title":"Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: stage 1 results of the Phase III SABRINA study (BO22334).","volume":"120","author":"Davies A","year":"2012","unstructured":"Davies A , MerliF, MihaljevikBet al. Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: stage 1 results of the Phase III SABRINA study (BO22334). ASH Annual Meeting Abstracts 120(21), 1629 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_3_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_3_2_3_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_3_2_4_2_1","unstructured":"Clinicaltrials.gov. A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera\/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera\/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin\u2019s Lymphoma (GALLIUM). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01332968)"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.13.134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:44Z","timestamp":1719124964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.13.134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,28]]},"references-count":114,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9,30]]}},"alternative-id":["10.2217\/fon.13.134"],"URL":"https:\/\/doi.org\/10.2217\/fon.13.134","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,28]]}}}